Immunotherapy of glioblastoma explants induces interferon-γ responses and spatial immune cell rearrangements in tumor center, but not periphery

• Published in: Science advances 2022-07, Vol.8 (26), p.eabn9440-eabn9440
• Main Authors: Shekarian, Tala, Zinner, Carl P, Bartoszek, Ewelina M, Duchemin, Wandrille, Wachnowicz, Anna T, Hogan, Sabrina, Etter, Manina M, Flammer, Julia, Paganetti, Chiara, Martins, Tomas A, Schmassmann, Philip, Zanganeh, Steven, Le Goff, Francois, Muraro, Manuele G, Ritz, Marie-Françoise, Phillips, Darci, Bhate, Salil S, Barlow, Graham L, Nolan, Garry P, Schürch, Christian M, Hutter, Gregor
• Format: Article
• Language: English
• Subjects: Biomedicine and Life Sciences; Cancer; Health and Medicine; SciAdv r-articles
• ISSN: 2375-2548; 2375-2548
• DOI: 10.1126/sciadv.abn9440

A patient-tailored, ex vivo drug response platform for glioblastoma (GBM) would facilitate therapy planning, provide insights into treatment-induced mechanisms in the immune tumor microenvironment (iTME), and enable the discovery of biomarkers of response. We cultured regionally annotated GBM explants in perfusion bioreactors to assess iTME responses to immunotherapy. Explants were treated with anti-CD47, anti-PD-1, or their combination, and analyzed by multiplexed microscopy [CO-Detection by indEXing (CODEX)], enabling the spatially resolved identification of >850,000 single cells, accompanied by explant secretome interrogation. Center and periphery explants differed in their cell type and soluble factor composition, and responses to immunotherapy. A subset of explants displayed increased interferon-γ levels, which correlated with shifts in immune cell composition within specified tissue compartments. Our study demonstrates that ex vivo immunotherapy of GBM explants enables an active antitumoral immune response within the tumor center and provides a framework for multidimensional personalized assessment of tumor response to immunotherapy.